No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LYEL240719C2500
- 0.05
- 0.000.00%
15min DelayTrading Jul 11 11:52 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume668 Open Interest2.50Strike Price0.00Turnover307.92%IV49.56%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1814Delta0.4479Gamma34.10Leverage Ratio-0.0172Theta0.0000Rho6.19Eff Leverage0.0005Vega
Intraday
- 5D
- Daily
News
Lyell Immunopharma Is Maintained at Buy by B of A Securities
Lyell Immunopharma Is Maintained at Buy by B of A Securities
B of A Securities Maintains Buy on Lyell Immunopharma, Lowers Price Target to $6
B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.
Lyell Immunopharmashares Are Trading Lower After the Company Released Initial Clinical Data From Its Phase 1 Trial of LYL797.
Lyell Immunopharmashares Are Trading Lower After the Company Released Initial Clinical Data From Its Phase 1 Trial of LYL797.
Lyell Immunopharma Price Target Cut to $1.00/Share From $6.00 by HC Wainwright & Co.
Lyell Immunopharma Price Target Cut to $1.00/Share From $6.00 by HC Wainwright & Co.
Express News | HC Wainwright & Co. Downgrades Lyell Immunopharma to Neutral, Lowers Price Target to $1
Express News | Lyell Immunopharma, Inc. : H.c. Wainwright Cuts to Neutral From Buy
Comments
Despite a strong cash runway, Lyell Immunopharma may face hurdles if additional funds are required, potentially diluting shares and affecting shareholder returns.
Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US$ +11.3%, $Cardiff Oncology(CRDF.US$ +9%, $Immatics(IMTX.US$ +8.3%, $IDEAYA Biosciences(IDYA.US$ +8%, $Lyra Therapeutics(LYRA.US$ +5.7%, $POINT Biopharma(PNT.US$ +5.7%, $Edgewise Therapeutics(EWTX.US$ +4.7%, $Concert Pharmaceuticals(CNCE.US$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US$ +3.2%, $Veracyte(VCYT.US$ +2.6%, $SpringWorks Therapeutics(SWTX.US$ +2.3%, ...
10
Read more